By Ahmed Aboulenein, Julie Steenhuysen and Michael Erman WASHINGTON (Reuters) -U.S. Health Secretary Robert Kennedy Jr. named ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already struggled to grow sales.

Nine years after selling Medivation to Pfizer for $14 billion, David Hung, M.D., is going toe to toe with the New York ...

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and ...

Pfizer Inc. (NYSE: PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug ...

FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the ...

While Pfizer said in its petition for mass tort designation that it expected many of the dismissed plaintiffs to refile their claims, that prediction has not come to fruition. Now, there appears to be ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety and promising objective response rates in patients with few treatment choices ...

OPKO Health strengthens finances by selling BioReference and focusing on drug development. Click here to read an analysis of ...

The Trump administration's cancellation of $766 million in contracts to develop mRNA vaccines against potential pandemic flu ...

Adar Poonawalla appeared to echo the opinions of Khushi Kapoor's character from Nadaaniyan, as he spoke about the disadvantages of distributing vaccines to the public for free, even during a pandemic.

Lyme disease, a potentially debilitating tick-borne infection if it is left untreated, is a growing problem in parts of Canada, with thousands of reported cases. But could there soon be a vaccine?